You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for NVS MLLT-1
NVS-MLLT-1 is a selective inhibitor of YEATS domain of MLLT1 and MLLT3 (IC50 values are 150 and 254 nM for MLLT1 and MLLT3, respectively). It shows selectivity for YEATS2/4 domains and over all bromodomains (CERC2 IC50 > 40 μM).
This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the NVS MLLT-1 probe summary on the SGC website.
Compound Libraries for NVS MLLT-1
Technical Data for NVS MLLT-1
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for NVS MLLT-1
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for NVS MLLT-1
The following data is based on the product molecular weight 385.47. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.59 mL||12.97 mL||25.94 mL|
|5 mM||0.52 mL||2.59 mL||5.19 mL|
|10 mM||0.26 mL||1.3 mL||2.59 mL|
|50 mM||0.05 mL||0.26 mL||0.52 mL|
References for NVS MLLT-1
References are publications that support the biological activity of the product.
Ni et al (2021) Structure and inhibitor binding characterization of oncogenic MLLT1 mutants. ACS Chem.Biol. 16 571 PMID: 33749253
If you know of a relevant reference for NVS MLLT-1, please let us know.
View Related Products by Product Action
Keywords: NVS MLLT-1, NVS MLLT-1 supplier, NVSMLLT-1, inhibitors, inhibits, bromodomains, selective, mixed-lineage, leukemia, translocated, to, 1, MLLT1, MLLLT3, super, elongation, complex, subunit, YEATSdomain, Bromodomains, 7482, Tocris Bioscience
Citations for NVS MLLT-1
Citations are publications that use Tocris products.
Currently there are no citations for NVS MLLT-1. Do you know of a great paper that uses NVS MLLT-1 from Tocris? Please let us know.
Reviews for NVS MLLT-1
There are currently no reviews for this product. Be the first to review NVS MLLT-1 and earn rewards!
Have you used NVS MLLT-1?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Epigenetics in Cancer PosterUpdated
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.